New York cardiologist Franz Messerli explains to Peter Goodwin why he doesn’t prescribe the popular diuretic hydrochlorothiazide as initial therapy for hypertension any more, as he announced in a “Late-Breaker” session at the European Meeting on Hypertension in Milan.
LISTEN
[audio:https://www.audiomedica.com/podcasting/cardio/090614FranzMesserliPODCAST.mp3]
Mandeep Mehra talks about his report in the New England Journal of Medicine on the inflammatory effects of COVID-19 infection and the implications...
Atrial fibrillation is prevented by exercise and life-long endurance athletes do not face the same elevated risks of stroke and heart disease from...
AMSTERDAM—Whether triple anti-thrombotic therapy should be accepted as generally the optimal approach for treating patients at high risk of having a...
AMSTERDAM — The SAVOR-TIMI 53 study in 16 000 patients has confirmed the efficacy of the DPP-4 inhibitor, saxagliptin, for controlling glycaemia in...
AMSTERDAM—Whether triple anti-thrombotic therapy should be accepted as generally the optimal approach for treating patients at high risk of having a...
AudioMedica News Young adults less likely to be diagnosed with hypertension than over 60s Play Episode Pause Episode 1x 00:00 / Subscribe RSS Feed...
